Clin Exp Allergy:肿瘤坏死因子α和白介素-5能够抑制嗅觉再生

2019-04-29 AlexYang MedSci原创

嗅觉障碍在过敏性鼻炎患者中是一种常见的情况。这种情况被认为是由于炎症引起的嗅觉粘膜结构性和功能性的变化产生的。然而,目前对过敏性鼻炎嗅觉功能障碍的病理学理解仍旧不清楚。最近,有研究人员在过敏性鼻炎中调查了嗅觉神经细胞损伤的原因。研究发现,嗅球细胞(OSCs)表达了神经干细胞的标记。为了调查神经分化,研究人员通过免疫细胞组化染色发现Tuji1、GFAP、O4和OSCs量均显著增加。在对照和过敏性鼻炎

嗅觉障碍在过敏性鼻炎患者中是一种常见的情况。这种情况被认为是由于炎症引起的嗅觉粘膜结构性和功能性的变化产生的。然而,目前对过敏性鼻炎嗅觉功能障碍的病理学理解仍旧不清楚。最近,有研究人员在过敏性鼻炎中调查了嗅觉神经细胞损伤的原因。

研究发现,嗅球细胞(OSCs)表达了神经干细胞的标记。为了调查神经分化,研究人员通过免疫细胞组化染色发现Tuji1、GFAP、O4和OSCs量均显著增加。在对照和过敏性鼻炎模型OSCs特性比较中,研究人员检测到过敏性鼻炎模型中显著更少的神经球,减少的克隆量和嗅觉神经干细胞标记物表达的减少。当OSCs通过一些主要的过敏细胞因子处理时,只有TNF-α表现出了对OSCs明显的抑制作用。有趣的是,IL-5与TNF-α组合能够对对OSCs的生存产生明显的抑制作用,而IL-5单独使用时并不表现出上述作用。更多的是,TNF-α与IL-5组合比两者单独使用时能够更加显著的增加凋亡因子的表达。另外,过敏性鼻炎小鼠模型表现出了凋亡表达的增加。

最后,研究人员指出,过敏性鼻炎模型表现出了更低的OSCs表达水平,并且TNF-α与IL-5组合对OSCs有凋亡作用。因此,这些细胞因子也许可以作为过敏性鼻炎患者嗅觉功能障碍的治疗靶标。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=366363, encodeId=aec836636346, content=好文章。好杂志,我也发过, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 17 17:36:35 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329235, encodeId=d3291329235c7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362945, encodeId=15431362945af, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372124, encodeId=2fe413e212453, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485475, encodeId=841114854e567, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365461, encodeId=7e5536546159, content=很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Mon Apr 29 13:39:49 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
    2019-05-17 营养医师

    好文章。好杂志,我也发过

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=366363, encodeId=aec836636346, content=好文章。好杂志,我也发过, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 17 17:36:35 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329235, encodeId=d3291329235c7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362945, encodeId=15431362945af, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372124, encodeId=2fe413e212453, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485475, encodeId=841114854e567, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365461, encodeId=7e5536546159, content=很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Mon Apr 29 13:39:49 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
    2019-05-01 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=366363, encodeId=aec836636346, content=好文章。好杂志,我也发过, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 17 17:36:35 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329235, encodeId=d3291329235c7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362945, encodeId=15431362945af, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372124, encodeId=2fe413e212453, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485475, encodeId=841114854e567, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365461, encodeId=7e5536546159, content=很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Mon Apr 29 13:39:49 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
    2019-05-01 millore
  4. [GetPortalCommentsPageByObjectIdResponse(id=366363, encodeId=aec836636346, content=好文章。好杂志,我也发过, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 17 17:36:35 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329235, encodeId=d3291329235c7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362945, encodeId=15431362945af, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372124, encodeId=2fe413e212453, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485475, encodeId=841114854e567, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365461, encodeId=7e5536546159, content=很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Mon Apr 29 13:39:49 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=366363, encodeId=aec836636346, content=好文章。好杂志,我也发过, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 17 17:36:35 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329235, encodeId=d3291329235c7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362945, encodeId=15431362945af, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372124, encodeId=2fe413e212453, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485475, encodeId=841114854e567, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365461, encodeId=7e5536546159, content=很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Mon Apr 29 13:39:49 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=366363, encodeId=aec836636346, content=好文章。好杂志,我也发过, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3e502075746, createdName=营养医师, createdTime=Fri May 17 17:36:35 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329235, encodeId=d3291329235c7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362945, encodeId=15431362945af, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372124, encodeId=2fe413e212453, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485475, encodeId=841114854e567, content=<a href='/topic/show?id=3879828e19d' target=_blank style='color:#2F92EE;'>#肿瘤坏死因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82871, encryptionId=3879828e19d, topicName=肿瘤坏死因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43077999209, createdName=ms7524819409032184, createdTime=Wed May 01 04:24:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365461, encodeId=7e5536546159, content=很好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b2e1935437, createdName=AlexYang, createdTime=Mon Apr 29 13:39:49 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
    2019-04-29 AlexYang

    很好!

    0

相关资讯

Asian Pac J Allergy Immunol:皮刺测试阴性慢性鼻炎患者屋尘螨局部过敏性鼻炎患病率研究

部过敏性鼻炎(LAR)是一种局部的过敏性响应且无系统特应性反应,可以通过特异性免疫球蛋白E(slgE)的局部产生和NAPT的阳性反应来鉴定(鼻腔过敏原激发试验)。最近,有研究人员调查了LAR在慢性鼻炎(CR)且对屋尘螨(Dp)皮刺测试阴性的成年人中的患病率情况,并且与非过敏性鼻炎(NAR)进行了比较来评估LAR的临床特性。研究包括了那些具有CR历史且对Dp皮刺测试阴性的患者,时间为2015年1月到

Sleep Breath:花粉水平能够影响过敏性鼻炎儿童的睡眠呼吸障碍严重度

过敏性鼻炎(AR)是儿童睡眠呼吸障碍(SDB)的常见风险因子。花粉是过敏性鼻炎的一种激发子,能够引起鼻炎、上呼吸道拥堵和阻塞。最近,有研究人员确定了是否花粉数量在诊断SDB多导睡眠图时能够影响其结果。研究包括了90名年龄在3-18岁的儿童,时间为当时区域的花粉数量数据可利用的2005年到2016年的10月1日和12月31日之间。所有的儿童均经历了过夜的睡眠监测SDB严重度评估。花粉分类为草花粉和其

Am J Rhinol Allergy:黄芪对卵清蛋白诱导的过敏性鼻炎影响研究

黄芪(AM)是一种传统的中国中草药,并用于过敏性疾病的治疗,但是治疗过敏性鼻炎(AR)的相关机制仍旧不清楚。最近,有研究人员调查了AM对AR的抗炎症影响和抗过敏机制。研究人员是利用卵清蛋白诱导的AR小鼠模型进行研究的。他们分析了过敏性症状、鼻粘膜嗜酸性细胞数量和鼻腔灌洗液中的炎症细胞水平,以及血清,免疫球蛋白E(lgE)、白介素-4(IL-4)、IL-5、IL-13、干扰素-γ(IFN-γ)和IL

Pediatr Allergy Immunol:城市和乡村地区营养和过敏性疾病分析

最近,有研究人员阐释和比较了城市和乡村过敏性疾病和致敏作用在SAFFA研究群体中的情况,并比较了孕妇饮食模式和营养状态情况。研究人员还评估了营养状态、母乳喂养、补充喂养模式与特应性疾病之间的关系。研究包括了1185名城市和398名乡村的儿童,年龄在12-36个月。研究发现,与农村的儿童相比,城市的过敏比例明显更高(哮喘9.0% vs 1.0%, 湿疹25.6% vs 2.0%, 鼻炎 3% vs

Clin Exp Otorhinolaryngol:虎耳草在过敏性鼻炎中的抗过敏作用研究

虎耳草提取物具有抗癌、抗过敏和抗氧化活性。最近,有研究人员调查了虎耳草提取物对过敏性鼻炎炎症中的作用。研究包括了4个不同的小组(组A:对照组;组B:过敏性鼻炎组;组C:300mg/kg处理组;组D:600mg/kg处理组),实验对象为BALB/c小鼠。研究发现,虎耳草提取物在组C和组D中对鼻症状、IL-13 mRNA的表达、鼻组织中嗜酸性细胞浸润/杯状细胞增生和OVA特异性lgE的产生均表现出了明

Rhinology:氮卓斯汀鼻喷雾能够抑制过敏性鼻炎患者的交感神经功能

盐酸氮卓斯汀(azelastine)鼻喷雾是一种组胺受体-1(H1)拮抗剂,经常用于治疗过敏性鼻炎来减轻症状。然而,氮卓斯汀对过敏性鼻炎患者鼻粘膜充血的影响还没有完全阐释且值得进一步探索。另外,氮卓斯汀对血管收缩响应的影响在体外也进行了调查。研究发现,甲氧胺添加能够引起鼻粘膜收缩,且表现为剂量依赖的方式。当甲氧胺添加剂量为10-6M或者更多时能够引起10-6M甲氧胺诱导的粘膜收缩的显著扩张响应。氮